Business
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia
WHIPPANY, N.J., December 02, 2025--Bayer announced today the start of its Phase III study SUNFLOWER, an investigational study evaluating the efficacy and safety of 52mg levonorgestrel-releasing intrauterine system Mirena® for the treatment of nonatypical endometrial hyperplasia (NAEH) in women.
About this update from Bayer Ag
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":318,"height":317,"url":"https://media.zenfs.com/en/business-wire.com/4237e96fb712406a7bf42dcd79933d33"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Yg1O37sCs6zaa5uVtW91PQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQxOTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/4237e96fb712406a7bf42dcd79933d33","width":318,"height":317}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Study further expands clinical development program of Bayer’s long-acting reversible intrauterine system Mirena® (levonorgestrel-releasing intrauterine system) 52 mg.","length":166,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Approximately 121 out of every 100,000 women develop nonatypical endometrial hyperplasia (NAEH), a benign form of endometrial thickening, each year.1 Currently, there are no approved medical treatment options for NAEH in the U.S.","length":229,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Mirena is globally available in more than 120 countries, and approved in the U.S. as a progestin-containing intrauterine system (IUS) indicated for prevention of pregnancy for up to 8 years and is also indicated for the treatment of heavy menstrual bleeding for women who choose to use intrauterine contraception as their method of contraception for up to 5 years.2 Mirena is not FDA approved for the treatment of NAEH.","length":419,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":814,"olType":false},{"type":"text","content":"WHIPPANY, N.J., December 02, 2025--(BUSINESS WIRE)--Bayer announced today the start of its Phase III study SUNFLOWER, an investigational study evaluating the efficacy and safety of 52mg levonorgestrel-releasing intrauterine system Mirena® for the treatment of nonatypical endometrial hyperplasia (NAEH) in women.","length":312,"tagName":"p"},{"type":"text","content":"NAEH is an abnormal thickening of the lining of the uterus, known as the endometrium, due to an imbalance between estrogen and progesterone levels. This condition is classified as nonatypical as the cells in the endometrium do not show signs of cancer. It can be asymptomatic, present with heavy or abnormal bleeding, or bleeding after menopause. If untrea...